We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+150.31%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
+$412M
Cap. Flow
+$25.7M
Cap. Flow %
2.41%
Top 10 Hldgs %
48.66%
Holding
270
New
60
Increased
70
Reduced
50
Closed
53

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$27.6M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$20.5M
3
ROIV icon
Roivant Sciences
ROIV
+$17.4M
4
ETNB
89bio
ETNB
+$12.6M
5
JANX icon
Janux Therapeutics
JANX
+$7.04M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$105M
2
PRTA icon
Prothena Corp
PRTA
+$14.6M
3
CGON icon
CG Oncology
CGON
+$7.97M
4
SAGE
Sage Therapeutics
SAGE
+$6.58M
5
VERV
Verve Therapeutics
VERV
+$5.27M

Sector Composition

Rank Sector Weight
1 Healthcare 83.19%
2 Financials 1.65%
3 Communication Services 0.09%
4 Consumer Discretionary 0.09%
5 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOSS icon
126
Gossamer Bio
GOSS
$87M
$559K 0.05%
212,531
-14,697
-6% -$32.4K
AEXA
127
American Exceptionalism Acquisition Corp
AEXA
$573M
$547K 0.05%
+50,000
New +$539K
IDYA icon
128
IDEAYA Biosciences
IDYA
$3.56B
$544K 0.05%
+20,000
New +$484K
LENZ
129
LENZ Therapeutics
LENZ
$168M
$541K 0.05%
+11,619
New +$427K
NGNE icon
130
Neurogene
NGNE
$712M
$531K 0.05%
30,633
+1,008
+3% +$20.2K
BHF icon
131
Brighthouse Financial
BHF
$3.49B
$531K 0.05%
+10,000
New +$488K
GTERU
132
Globa Terra Acquisition Corp Units
GTERU
$509K 0.05%
+50,000
New +$508K
PHAT icon
133
Phathom Pharmaceuticals
PHAT
$692M
$505K 0.05%
42,900
-20,524
-32% -$212K
USFR icon
134
WisdomTree Floating Rate Treasury Fund
USFR
$18.4B
$503K 0.05%
10,000
– –
KZR
135
DELISTED
Kezar Life Sciences
KZR
$487K 0.05%
124,967
-22,437
-15% -$92K
KURA icon
136
Kura Oncology
KURA
$850M
$487K 0.05%
55,000
+20,700
+60% +$148K
ASMB icon
137
Assembly Biosciences
ASMB
$529M
$485K 0.05%
+18,947
New +$416K
DYN icon
138
Dyne Therapeutics
DYN
$4.9B
$476K 0.04%
37,663
+14,600
+63% +$167K
KPRX icon
139
Kiora Pharmaceuticals
KPRX
$11.7M
$467K 0.04%
167,941
+830
+0.5% +$2.28K
APLS
140
DELISTED
Apellis Pharmaceuticals
APLS
$453K 0.04%
20,000
+3,000
+18% +$70K
INSP icon
141
Inspire Medical Systems
INSP
$1.74B
$445K 0.04%
+6,000
New +$607K
NVCR icon
142
NovoCure
NVCR
$1.91B
$439K 0.04%
+34,000
New +$454K
INBS icon
143
Intelligent Bio Solutions
INBS
$4.74M
$435K 0.04%
+42,643
New +$687K
SGRY icon
144
Surgery Partners
SGRY
$2.03B
$433K 0.04%
20,000
-20,000
-50% -$446K
GPCR icon
145
Structure Therapeutics
GPCR
$3.78B
$426K 0.04%
15,200
+200
+1% +$3.98K
AVTX icon
146
Avalo Therapeutics
AVTX
$983M
$412K 0.04%
32,393
-72,337
-69% -$622K
TENX icon
147
Tenax Therapeutics
TENX
$503M
$407K 0.04%
53,428
-102,129
-66% -$624K
VTGN icon
148
VistaGen Therapeutics
VTGN
$12.8M
$401K 0.04%
113,062
-307,703
-73% -$919K
ORKA
149
Oruka Therapeutics
ORKA
$5.96B
$401K 0.04%
20,840
-121,940
-85% -$1.81M
NVCR icon
150
CALL
NovoCure
NVCR
$1.91B
$388K 0.04%
+30,000
New +$401K
4 5
6
7 8

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, ADAR1 Capital Management held 270 positions worth $1.06B, up 63% from $652M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

ADAR1 Capital Management's Q3 2025 filing shows 60 new, 70 increased, 50 reduced and 53 closed positions. Its largest new stake was Invivyd: 7,370,987 shares worth $8.11M. The largest sale was Abivax, an estimated $105M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier, followed by Financials and Communication Services.

  • ADAR1 Capital Management's largest Q3 2025 buy was Invivyd: 7,370,987 shares worth $8.11M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2025, an estimated $27.6M increase.
  • ADAR1 Capital Management's biggest Q3 2025 reduction was Abivax, cutting an estimated $105M.
  • ADAR1 Capital Management fully exited Sage Therapeutics in Q3 2025, selling an estimated $6.58M.
  • ADAR1 Capital Management's ten largest holdings make up 49% of its $1.06B portfolio in Q3 2025.
  • ADAR1 Capital Management opened 60 new positions and closed 53 in Q3 2025.
  • ADAR1 Capital Management's portfolio value rose 63% quarter-over-quarter to $1.06B.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.